Nereus (tradipitant) is a new prescription medicine approved by the FDA to help prevent nausea and vomiting caused by motion (motion sickness) in adults, such as during car rides, boat trips, or flights.
Motion sickness happens when the brain receives conflicting signals from the eyes, the inner ear (which controls balance), and the body’s sense of position. This sensory mismatch can trigger the release of a chemical called substance P, which activates neurokinin-1 (NK-1) receptors in the brain. Together, these signals can cause nausea and vomiting, leading to motion sickness.
Key Details on NEREUS™ (tradipitant):
- Approval: Approved by the U.S. FDA in late December 2025 for preventing motion sickness.
- Mechanism: Acts as a neurokinin-1 (NK-1) receptor antagonist, which targets the pathway for nausea and vomiting.
- Effectiveness: In trials, it significantly reduced vomiting compared to placebos, particularly during challenging conditions like sea travel.
- Availability: Vanda Pharmaceuticals planned to launch the drug in the months following approval.